Delving into the Latest Updates on ZHB-202 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

+ [2]

Target-

Mechanism-

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Acute Lymphoblastic LeukemiaExtranodal NK-T-Cell Lymphoma

Inactive Indication-

Originator Organization

Changzhou Qianhong Biopharma Co., Ltd.

Active Organization

Changzhou Qianhong Biopharma Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要研究目的：？评价QHRD102注射液剂量递增在复发或难治性急性淋巴细胞白血病（ALL）及结外NK/T细胞淋巴瘤（ENKTL）患者的安全性、耐受性，以确定最大耐受剂量（MTD），剂量限制性毒性（DLT）；？研究QHRD102注射液的药代动力学（PK）特征及药效学（PD）特征。次要研究目的：？研究QHRD102注射液的免疫原性；？评估QHRD102注射液治疗复发或难治性ALL及ENKTL的初步疗效。

[Translation]

Main study objectives: ? To evaluate the safety and tolerability of QHRD102 injection in patients with relapsed or refractory acute lymphoblastic leukemia (ALL) and extranodal NK/T-cell lymphoma (ENKTL) to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT); ? To study the pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of QHRD102 injection. Secondary study objectives: ? To study the immunogenicity of QHRD102 injection; ? To evaluate the preliminary efficacy of QHRD102 injection in the treatment of relapsed or refractory ALL and ENKTL.

Start Date-

Sponsor / Collaborator

Zonhon Biopharma Institute, Inc.

[+1]

ChiCTR2100042416 / RecruitingPhase 1

A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QHRD102 in patients with relapsed or refractory acute lymphoblastic leukemia (ALL) and extranodal NK/T cell lymphoma (ENKTL) in adults

Start Date01 Feb 2021

Sponsor / Collaborator-

100 Clinical Results associated with ZHB-202

Login to view more data

100 Translational Medicine associated with ZHB-202

Login to view more data

100 Patents (Medical) associated with ZHB-202

Login to view more data

100 Deals associated with ZHB-202

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Lymphoblastic Leukemia	Phase 1	CN	Changzhou Qianhong Biopharma Co., Ltd.	18 Feb 2021
Extranodal NK-T-Cell Lymphoma	Phase 1	CN	Changzhou Qianhong Biopharma Co., Ltd.	18 Feb 2021